The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L antibody Avelumab.La présente invention concerne une nouvelle formulation d'anticorps anti-PD-L1. En particulier, l'invention concerne une formulation pharmaceutique aqueuse de l'anticorps anti-PD-L, l'Avélumab.